For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
HOME > REGULATORY
REGULATORY
- CSIMC Approves Listing of 12 APIs, Parjeta Gets 5% Premium for Usefulness
August 23, 2013
- MHLW Proposes Plan to Downwardly Revise NHI Prices of Combination Drugs and Drugs Obtained as a Result of Optical Resolution of Racemic Bodies
August 23, 2013
- “Zero Risk” of Tumorigenicity from Products Using iPS Cells Cannot Be Guaranteed at Present: PMDA’s Science Board
August 23, 2013
- Health Ministry Notifies Prefectures of Approval for Xolair, Other Products
August 22, 2013
- MHLW to Draft New Guidance on Companion Diagnostics by End of 2013: Director Sato of ELD
August 20, 2013
- Takeda’s OBLEAN Joins Aug. 22 Review List of PAFSC 1st Committee
August 19, 2013
- 30-Plus Companies Gain Approval for Livalo, Valtrex Generics towards December Listing
August 16, 2013
- Case of Chagas Disease Confirmed through Blood Donation Raises Concern Over Secondary Infection
August 16, 2013
- 3 Ex-Officials of MHLW, NHO Affiliated with Novartis in 2010, Govt Says
August 15, 2013
- PMDA Meets All Targets for FY2012 with Exception of Time Spent by Applicants for Non-Priority Products
August 15, 2013
- Can Japan Become the Global Leader in Drug Discovery? New Vision for Pharmaceutical Industry Drops Company Categories Included in the Previous One
August 15, 2013
- PAFSC 2nd Committee to Review GSK’s Combination Asthma Drug on Aug. 26
August 14, 2013
- MHLW Compiles Report on Expert Council on Future Cancer Research
August 14, 2013
- EAD Director Visits 5 Hospital HQ to Urge Early Price Settlements, Greeted with Mixed Enthusiasm
August 13, 2013
- 41,254 ADR Reports Received from Marketing Authorization Holders in FY2012: MHLW
August 13, 2013
- Japan NIH HQ to Orchestrate Allocation of 100 Billion Yen for R&D Budgets, Starting with FY2014 Requests
August 12, 2013
- 1st Committee on Drugs to Discuss Pediatric Indication for Kyowa Kirin’s Nesp
August 12, 2013
- MHLW Diovan Committee: 3 More Universities Give 1st Probe Updates, SMART Data Rapped “Sloppy”
August 12, 2013
- MHLW Taps 12 Experts to Serve on Diovan Study Committee; J-CLEAR’s Kuwajima, JAMS’s Sone on the List
August 9, 2013
- PMDA to Make Public Adverse Reactions Reported by Patients by Year-End
August 8, 2013
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…